LAVA Therapeutics NV — Investor Presentation (September 2022)
35 slides from LAVA Therapeutics NV's investor presentation, Sep 30, 2022
Slide 1: Fighting Cancer with Precision Gammabody Platform Corporate Presentation
1 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation September 2022
Slide 2: Legal Disclosure: Forward-looking Statements
2 Legal Disclosure: Forward - looking Statements This presentation contains forward - looking statements, including with respect to the company’s anticipated growth and clinical development plans, including the timing of clinical trials .. Words such as “anticipate,” “believe,” “could,” “will,” “may
Slide 3: Investment Highlights
3 Investment Highlights Clinical - Stage Company Developing Bispecific Gamma Delta T Cell Engagers © LAVA Therapeutics 2022 • Gammabody ™ Platform - Bispecific antibodies linking V 9V 2 T cells to tumor targets to l everage the unique anti - tumor potential of V 9V 2 T cells • Strongly enhan
Slide 4: Differentiated Gammabody Pipeline in Hematologic & Solid Tumor Indications
4 Differentiated Gammabody ™ Pipeline in Hematologic & Solid Tumor Indications Solid Tumor Hematologic malignancy MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate - specific membrane antigen EGFR: epidermal growth factor receptor mCRPC : metastatic ca
Slide 5: Established Leadership with Proven Experience in Drug Discovery & Development
5 Established Leadership with Proven Experience in Drug Discovery & Development Ton Adang, PhD CDO Paul Parren, PhD EVP, Head of R&D Hans van der Vliet, MD, PhD CSO Steve Hurly, MSc, MBA President & CEO • 25+ years leadership experience in life sciences industry • Former President & CEO, Sesen Bio,
Slide 6: Gamma Delta T Cells
6 Gamma Delta T Cells Uniquely suited for an anti - cancer T cell engager approach V 9V 2 T Cells
Slide 7: Vγ9Vδ2 T Cells Uniquely Positioned to Leverage Innate & Adaptive Immunity
7 V 9V 2 T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity V 9V 2 T cells are an abundant, homogeneous effector cell population associated with positive outcomes in cancer patients Adaptive Immunity Innate Immunity Yeung MM, et al. Gut 2000; 47:215 Kimura Y, et al. Cance
Slide 8: Gamma Delta T Cells Present in Many Cancers & Correlated With Favorable Prognosis
8 T Cells Present in Many Cancers & Correlated With Favorable Prognosis Adapted from Tosolini M et al. Oncoimmunology 2017; 6, e1284723 T cells indicate highest correlation with favorable outcome among all leukocyte subsets analyzed V 9V 2 T cells are present across a wide array of hematol
Slide 9: LAVA's Proprietary Gammabody Platform
9 LAVA’s Proprietary Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers
Slide 10: Systemic Activation of Vγ9Vδ2 Cells Showed Promise
10 Systemic Activation of V 9V 2 T Cells Showed Promise • Systemic activation and proliferation via treatment with V 9V 2 T cell - based therapy (synthetic phosphoantigens ( BrHPP ) / aminobisphosphonates ± low - dose IL - 2) Early attempts with V 9V 2 T cell - based therapy showed promi
Slide 11: Off-the-Shelf Gammabody Platform Directing Vγ9Vδ2 Cells to Cancer Cells
11 Off - the - Shelf Gammabody ™ Platform: Enhances Innate Tumor Recognition by Directing V 9V 2 T Cells to the Cancer Cells LAVA’s Gammabody ™ adds tumor antigen - specific recognition, while retaining stress signal recognition, to target and activate V 9V 2 T cells to induce both direct tu
Slide 12: Cascade Response – Potential Translation to Favorable Therapeutic Window
12 Cascade Response – Potential Translation to Favorable Therapeutic Window Efficacy: Safety: In addition to direct tumor cell killing , V 9 V 2 T cells have the potential to orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor m
Slide 13: Potent Killing of Cancer Cells in Preclinical Models
13 Potent Killing of Cancer Cells in Preclinical Models Highly Potent Durable Dose Dependent and Serial Killing Conditional Activation EGFR Gammabody ™ - Induced Cytotoxicity CD1d Gammabody ™ Triggers Lysis of CCRF - CEM Tumor Cells Killing of Primary Colorectal Cancer Cells by EGFR Gammabody ™ Sust
Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models
14 Expansion & Cascade Response Without Treg Activation in Preclinical Models Gammabody ™ can induce robust gamma delta T cell expansion and can amplify the anti - tumor immune response via downstream activation of other immune cells while avoiding co - activation of immunosuppressive T cells such a
Slide 15: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells
15 Gammabody ™ Can Selectively Kill Cancer Cells W hile Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models • 2:1 ratio ( T cells : Target cells) • Similar CD20 expression levels on C1R neo and B - cells CD20 Gammabody ™ Mediated Killing PSMA Gammabody ™ Mediated Killing Prefer
Slide 16: Fully Cross-Reactive Surrogates Well-Tolerated in Non-Human Primates
16 Fully Cross - Reactive bsTCEs are Well - Tolerated in Non - Human Primates • Mild to no clinical signs of toxicity • Low cytokine spike, which did not result in CRS • No clinical chemistry abnormalities • No histopathological abnormalities • Gammabody ™ detectable on peripheral blood and lymph
Slide 17: LAVA-051 Activates Vγ9Vδ2 T Cells and iNKT Cells by Targeting CD1d
17 LAVA - 051 Activates T Cells and iNKT Cells by Targeting CD1d for the Treatment of CLL, MM & AML
Slide 18: LAVA-051: First-in-Class Gammabody Targeting CD1d
18 LAVA - 051: First - in - Class Gammabody ™ Targeting CD1d • Principal Mechanism of Action ( MoA ): Targets and activates V 9V 2 T cells in the presence of CD1d - expressing tumor cells • Secondary MoA : Activates iNKT cells against CD1d - expressing tumor cells ‒ Direct cytotoxicity against C
Slide 19: LAVA-051: Targeting CD1d for Hematological Cancers
19 LAVA - 051: Targeting CD1d for Hematological Cancers CD1d is expressed on tumors cells in a high proportion of patients with CLL, MM & AML CD1d expression (MF index) Isotype Isotype Isotype 0.5 1 2 4 8 16 32 64 128 N=39 N=51 N=85 AML MM CLL © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics
Slide 20: LAVA-051 Phase 1/2a Initiated in Hematological Malignancies
20 CLL AND MM AML (highest dose levels only) Optional adjustments: • Dosing frequency • Dose level • # cohorts CLL (n=20) MM (n=20) Twice - weekly dosing AML (n=20) LAVA - 051 Phase 1/2a Initiated in Hematological Malignancies Phase 1 first 4 cohorts dose escalation data presented at ASCO 2022; Addi
Slide 21: LAVA-051 Phase 1/2a: Extensive Biomarker Analysis
21 Biomarker analysis to validate whether LAVA’s Gammabody ™ platform performs in humans as predicted based on preclinical data LAVA - 051 Phase 1/2a: Extensive Biomarker Analysis Pharmacodynamics Cytokines (IL - 1β, IL - 2, IL - 6, IL - 8, TNF - α, IFN - γ, GM - CSF) B inding of LAVA - 051: V 9V
Slide 22: LAVA-051 Patient characteristics and time on treatment
22 LAVA - 051 - Patient characteristics and time on treatment MM/CLL 3/3 Male/Female 5/1 Median age (range) 66 (60 - 75) Prior therapies, median (range) – MM/CLL 5 (4 - 6) 4 (3 - 5) DLT period PD PD PD PD COVID COVID © LAVA Therapeutics 2022
Slide 23: LAVA-051 Adverse events
23 LAVA - 051 - Adverse events NS = not suspected; S = suspected A : Drug hypersensitivity Gr3 reported for CLL patient to allopurinol administered as TLS prophylaxis; allergy to allopurinol con firmed through repeat occurrence to single agent prophylaxis. B : Fever Gr2 reported for CLL patient in c
Slide 24: LAVA-051 Pharmacodynamics
24 LAVA - 051 - Pharmacodynamics • V 9 V 2 T cell activation markers (CD 25 and CD 69 ) consistently upregulated following dosing, in each dose cohort • Maximum measured V 9 V 2 T cell receptor occupancy (RO) increased with higher dose cohorts • iNKT cell activation was assessable, and obser
Slide 25: LAVA-051 Potential signs of activity
25 LAVA - 051 – Potential signs of activity 0 25 50 75 100 125 0.01 0.1 1 Treatment days Cell count (x10 9 /L) Lymphocytes Clonal B cells R/R = Relapsed/Refractory; iwCLL = international workshop on C hronic Lymphocytic L eukemia. Permission for photo obtained. MM • High risk MM patient ( 45 g) •
Slide 26: Conclusions
26 Conclusions • LAVA - 051 is the first of a novel class of bispecific T cell engagers with expected broad therapeutic window – Bispecific single domain antibody engaging CD 1 d and V 2 - TCR chain of V 9 V 2 - T cells to mediate potent killing – Low potential for CRS observed in preclinic
Slide 27: LAVA-1207 Activates Vγ9Vδ2 T Cells by Targeting PSMA for mCRPC
27 LAVA - 1207 Activates T Cells by Targeting PSMA for the Treatment of mCRPC
Slide 28: LAVA-1207: Targeting PSMA for Prostate Cancer
28 LAVA - 1207: Targeting PSMA for Prostate Cancer PSMA + tumor cells LAVA - 1207 VHH - Fc ~80kD V 9V 2 T cells • Specifically targets and mediates activation of V 9 V 2 T cells against PSMA - expressing tumor cells • PSMA is a well - validated tumor target ‒ Mediates PSMA - dependent activa
Slide 29: LAVA-1207 Phase 1/2a in Metastatic Castration-Resistant Prostate Cancer
29 LAVA - 1207 Phase 1/2a in Metastatic Castration - Resistant Prostate Cancer ( mCRPC ) Therapy Refractory mCRPC Optional Adjustments: • Dosing frequency • Dose level • # cohorts Therapy Refractory mCRPC (n=30) Dosing: Every 2 Weeks LAVA - 1207 Phase 1/2a Initiated; Patient Recruitment Underway Dos
Slide 30: Key Preclinical Programs
30 Key Preclinical Programs
Slide 31: Potential for LAVA-1223 Across EGFR-Expressing Solid Tumors
31 Potential for LAVA - 1223 Across a Number of EGFR - Expressing Solid Tumors Data on file: LAVA Therapeutics N.V. and Janssen Biotech Inc. 0 20 40 60 80 100 Bladder Breast Colon Glioma Head & Neck NSCLC Ovarian Pancreatic RCC Percentage overexpression range EGFR Expression by Tumor Type (Range) Su
Slide 32: LAVA-1266 Shows Promise for Hematological Malignancies
32 LAVA - 1266 Shows Promise for Hematological Malignancies 0.01 0.1 1 10 100 1000 0 20 40 60 80 100 CD123 Gammabody TM Concentration [pM] Specific cell death of primary AML cells (%) EC50 ~ 8 pM 0.01 0.1 1 10 100 1000 0 20 40 60 80 100 CD123 Gammabody TM Concentration [pM] THP-1 cell line cytotoxic
Slide 33: dp) —@® (Ss {e) _— ep) & =
dp) —@® (Ss {e) _— ep) & =
Slide 34: Two Lead Programs in Clinic with Near-Term Milestones
34 • 3L+ mCRPC pts • Adoptive FIH study design, dose escalation • Key data: Safety, initial anti - tumor activity, estimation of therapeutic window • Initial study in relapsed/refractory MM, CLL; relapsed/refractory AML added at biological relevant dose(s) • Adoptive FIH study design, dose escalatio
Slide 35: September
35 Corporate Presentation September 2022
LAVA Therapeutics — Investor Presentation (September 2022) on 6ix